The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Dr. Roseff and his colleagues are conducting a study to evaluate the effectiveness of a novel substance (Inofolic Plus®) in improving oocyte (egg) parameters in subfertile female patients, as measured through Anti-Mullerian Hormone (AMH) blood levels.
| Condition | Intervention |
|---|---|
|
Infertility, Female |
Dietary Supplement: Inofolic Plus |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | The Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve Parameters in Subfertile Women |
- Potential Effects of Inofolic Plus on Abnormal Ovarian Reserve (AMH Levels) [ Time Frame: Three Months ] [ Designated as safety issue: No ]Women will receive Infolic Plus nightly for up to 90 days. Baseline AMH blood levels will be analyzed, and AMH titers will be checked monthly thereafter for the 90 day duration of the study.
| Enrollment: | 15 |
| Study Start Date: | February 2011 |
| Study Completion Date: | February 2012 |
| Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Inofolic Plus
Patients are given Inofolic Plus to see if the AMH changes over a period of up to 90 days.
|
Dietary Supplement: Inofolic Plus
Inofolic Plus contains folic acid and myoinositol and melatonin
Other Name: folic acid, myoinositol, and melatonin in combination
|
Detailed Description:
Inofolic Plus® contains several nutritional elements including myo-inositol, melatonin, and folic acid. Myo-inositol was found to be helpful in improving egg quality and/or quantity in women with an ovarian abnormality called polycystic ovarian syndrome as well as in women without the disorder undergoing assisted reproduction.
Myo-inositol and folic acid are compounds that belong to the family of B-vitamins. Inositol is normally found in several types of foods. Folic acid has been found to significantly decrease the incidence of certain types of birth defects in women taking sufficient amounts prior to and during pregnancy. Preliminary studies using myo-inositol and folic acid demonstrated improvement in egg quality in-vitro and in-vivo as well as multiple metabolic parameters in women with irregular menstrual cycles and certain types of hormone imbalances.
Melatonin is a potent antioxidant. Folic acid is not classified as an antioxidant but has been reported to have antioxidant-like activity. Antioxidants have been given to infertile men for years to improve egg parameters. Most recently, studies have documented the efficacy of antioxidant treatment on human egg parameters and fertilization rates, especially in the setting of in-vitro fertilization (IVF). Inofolic Plus® contains melatonin and folic acid. Dr. Roseff hypothesizes that Inofolic Plus® may be effective in correcting abnormal egg parameters in women. A woman may have abnormal eggs from being exposed to environmental and workplace toxins that generate oxygen free radicals in her body (known as reactive oxygen species, or ROS). These ROS circulate through the blood stream and can enter the ovaries where eggs are stored. Eggs may be sensitive to ROS, and damage from the ROS may result in poor egg quality or quantity or both. The combination of nutrients and antioxidants in Inofolic Plus® may help to correct these abnormalities. Melatonin is a natural hormone normally found in the brain. This hormone helps regulate sleep/wake cycles. Melatonin levels increase during the evening and remain high during the night. This elevated level of melatonin is thought to induce drowsiness. It is because of this effect that we recommend taking Inofolic Plus® in the late evening near bedtime.
Eligibility| Ages Eligible for Study: | 18 Years to 42 Years |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Female between 18 - 42 years of age
- Diagnosed with "Diminished Ovarian Reserve" (DOR)
Exclusion Criteria:
- Ongoing history of illicit drug or tobacco use
- Ovarian surgery within 90 days of signing the consent form
Contacts and Locations| United States, Florida | |
| Palm Beach Center for Reproductive Medicine | |
| Wellington, Florida, United States, 33414 | |
| Principal Investigator: | Scott Roseff, MD | Palm Beach Center for Reproductive Medicine |
More Information
Publications:
| Responsible Party: | Scott Roseff, MD, Principal Investigator, Palm Beach Center for Reproductive Medicine |
| ClinicalTrials.gov Identifier: | NCT01290432 History of Changes |
| Other Study ID Numbers: | Roseff-01 |
| Study First Received: | February 3, 2011 |
| Last Updated: | May 24, 2012 |
| Health Authority: | Italy: National Institute of Health |
Keywords provided by Palm Beach Center for Reproductive Medicine:
|
female fertility ovarian reserve oocyte quality oocyte quantity antimullerian hormone |
AMH dietary supplements inofolic plus myoinositol folic acid |
Additional relevant MeSH terms:
|
Infertility Infertility, Female Genital Diseases, Male Genital Diseases, Female Folic Acid Vitamin B Complex Inositol Melatonin Vitamins Micronutrients Growth Substances |
Physiological Effects of Drugs Pharmacologic Actions Hematinics Hematologic Agents Therapeutic Uses Central Nervous System Depressants Central Nervous System Agents Antioxidants Molecular Mechanisms of Pharmacological Action Protective Agents |
ClinicalTrials.gov processed this record on June 17, 2013